Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results

08 May, 2013, 16:01 ET from Avanir Pharmaceuticals, Inc.

ALISO VIEJO, Calif., May 8, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today reported financial results for the three and six months ended March 31, 2013.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

Quarterly Financial Highlights

  • Total company net revenues of $17.4 million
  • Gross and net NUEDEXTA® sales increased to $20.8 million and $16.5 million, respectively, representing growth of 14% and 11% versus the previous quarter
  • Cash, cash equivalents, and restricted investments of $70.2 million as of March 31, 2013.

"Avanir achieved a major milestone with the exciting news regarding the positive CHMP opinion for NUEDEXTA in Europe. This is a significant moment in the evolution of the company towards its goal of becoming a leading mid-cap biopharmaceutical company," said Keith A. Katkin, president and CEO of Avanir.  "Additionally, we continue to execute in the U.S. as demonstrated by our commercial and clinical progress. We enter the second half of fiscal 2013 with strong momentum, a broad CNS pipeline and a continued focus on building our business."

Fiscal 2013 Second Quarter Results

  • Total net revenues for the quarter ended March 31, 2013 were $17.4 million, compared with $10.0 million for the comparable quarter in fiscal 2012, representing 74% year-over-year growth. Total net revenues consist of NUEDEXTA net revenue and royalty revenue from Abreva®.
  • Total operating expenses, excluding cost of sales and share-based compensation were $30.1 million in the second quarter of fiscal 2013, compared with $25.3 million in the comparable period in fiscal 2012.
  • Cash used in operations was $9.6 million in the second quarter of fiscal 2013.
  • Net loss for the fiscal 2013 second quarter was $16.5 million, or $0.12 per share, compared with a net loss of $17.0 million, or $0.13 per share, for the same period in fiscal 2012.

Fiscal 2013 Six-Month Results

  • Total net revenues for the first six-months of fiscal 2013 totaled $34.0 million, compared with $17.2 million for the first six months of fiscal 2012.
  • Total operating expenses, excluding cost of sales and share-based compensation were $55.4 million in the first six-months of fiscal 2013, compared to $47.0 million in the comparable period for fiscal 2012.
  • Cash used in operations was $22.3 million in the first six months of fiscal 2013.
  • Net loss for the first six-months of fiscal 2013 was $28.6 million, or $0.21 per share, compared with a net loss of $33.0 million, or $0.25 per share for the comparable period in fiscal 2012.

NUEDEXTA Revenue For the quarter ended March 31, 2013, the company reported NUEDEXTA gross and net revenue of $20.8 million and $16.5 million respectively. Second quarter fiscal 2013 NUEDEXTA net revenue increased 81% versus the previous year and 11% over the previous quarter.

Cash, Cash Equivalents & Marketable Securities As of March 31, 2013 Avanir had cash, cash equivalents and restricted investments totaling $70.2 million, including cash and cash equivalents of $67.9 million.

Business Highlights

  • The company reported an eighth consecutive quarter of NUEDEXTA unit growth in both business channels with 13% retail and 4% institutional growth.
  • The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for NUEDEXTA, recommending it be approved in two dosage strengths for the treatment of pseudobulbar affect (PBA), irrespective of neurologic cause.
  • The company appointed Corinne Nevinny, a seasoned life sciences executive with broad healthcare industry experience, to the company's board of directors.

Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2013 second quarter financial results today, May 8, 2013, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1- 877 703 6106 for domestic callers or +1- 857 244 7305 for international callers, and entering passcode 62763985. Those interested in listening to the conference call live via the internet may do so by visiting http://ir.avanir.com.

About NUEDEXTA NUEDEXTA is an innovative combination of two well-characterized components; dextromethorphan hydrobromide (20 mg), the ingredient active in the central nervous system, and quinidine sulfate (10 mg), a metabolic inhibitor enabling therapeutic dextromethorphan concentrations. NUEDEXTA acts on sigma-1 and NMDA receptors in the brain, although the mechanism by which NUEDEXTA exerts therapeutic effects in patients with PBA is unknown.

NUEDEXTA Important Safety Information NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurological conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state.

Studies to support the effectiveness of NUEDEXTA were performed in patients with amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS). NUEDEXTA has not been shown to be safe and effective in other types of emotional lability that can commonly occur, for example, in Alzheimer's disease and other dementias.

NUEDEXTA and certain other medicines can interact, causing serious side effects. If you take certain drugs or have certain heart problems, NUEDEXTA may not be right for you.

NUEDEXTA causes dose-dependent QTc prolongation. When initiating NUEDEXTA in patients at risk for QT prolongation and torsades de pointes, electrocardiographic (ECG) evaluation should be conducted at baseline and 3-4 hours after the first dose.

The most common adverse reactions are diarrhea, dizziness, cough, vomiting, asthenia, peripheral edema, urinary tract infection, influenza, increased gamma-glutamyltransferase, and flatulence. NUEDEXTA may cause dizziness.

These are not all the risks from use of NUEDEXTA. Please refer to full Prescribing Information at www.NUEDEXTA.com.

About Avanir Pharmaceuticals, Inc. Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. As part of our commitment, we have extensively invested in our pipeline and are dedicated to advancing medicines that can substantially improve the lives of patients and their loved ones. For more information about Avanir, please visit www.avanir.com.

AVANIR® and NUEDEXTA® are trademarks or registered trademarks of Avanir Pharmaceuticals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development and the potential benefits of its commercialized products and products under development are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with Avanir's operating performance and financial position, the market demand for and acceptance of Avanir's products domestically and internationally, research, development and commercialization of new products domestically and internationally, obtaining additional indications, obtaining and maintaining regulatory approvals domestically and internationally, and other risks detailed from time to time in the Company's most recent Annual Report on Form 10-K and other documents subsequently filed with or furnished to the Securities and Exchange Commission. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Avanir Investor & Media Contact Ian Clements, PhD ir@avanir.com +1 (949) 389-6700

 

AVANIR PHARMACEUTICALS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

March 31,

September 30,

2013

2012

(unaudited)

(audited)

ASSETS

Current assets:

     Cash and cash equivalents

$  67,859,426

$   69,778,406

     Restricted cash and cash equivalents

654,624

652,913

     Trade receivables, net

9,679,775

7,231,759

     Inventories, net

428,969

415,475

     Prepaid expenses and other current assets

2,570,074

2,434,590

     Restricted short-term investment

-

401,550

          Total current assets

81,192,868

80,914,693

Restricted long-term investments

1,303,938

1,302,136

Property and equipment, net

1,680,317

1,808,594

Non-current inventories, net

908,366

908,364

Other assets

625,196

1,078,009

       TOTAL ASSETS

$  85,710,685

$   86,011,796

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

    Accounts payable, accrued expenses and other liabilities

$  20,734,658

$   15,598,666

    Current portion of note payable

7,812,014

2,162,263

    Current portion of deferred royalty revenues

2,557,464

2,557,464

       Total current liabilities

31,104,136

20,318,393

Accrued expenses and other liabilities, net of current portion

1,073,265

666,179

Note Payable

21,325,055

26,698,263

Deferred royalty revenues, net of current portion

117,022

1,491,854

        Total liabilities

53,619,478

49,174,689

         Total stockholders' equity

32,091,207

36,837,107

TOTAL LIABILITIES AND STOCKHOLDERS'  EQUITY

$  85,710,685

$   86,011,796

 

AVANIR PHARMACEUTICALS, INC.

CONDENSED STATEMENT OF OPERATIONS

Three Months Ended March 31,

Six Months Ended March 31,

2013

2012

2013

2012

REVENUES

   Net product sales

$  16,535,059

$    9,141,873

$   31,414,321

$   14,630,636

   Revenues from royalties

899,129

898,515

2,525,139

2,574,635

   Revenue from research grant services

-

-

15,000

-

           Total revenues

17,434,188

10,040,388

33,954,460

17,205,271

OPERATING EXPENSES

   Cost of product sales

933,426

534,345

1,771,555

844,148

   Cost of research grant services

69,090

-

78,488

-

   Research and development

8,874,298

6,395,155

15,522,389

10,139,670

   Selling and marketing

16,061,408

14,814,013

29,583,827

28,596,850

   General and administrative

6,978,684

5,346,991

13,517,087

10,639,173

           Total operating expenses

32,916,906

27,090,504

60,473,346

50,219,841

Loss from operations

(15,482,718)

(17,050,116)

(26,518,886)

(33,014,570)

OTHER INCOME (EXPENSE)

   Interest income

15,065

7,882

34,396

22,173

   Interest expense

(1,059,245)

-

(2,118,490)

-

   Other, net

197

75

197

4,081

Loss before provision for income taxes

(16,526,701)

(17,042,159)

(28,602,783)

(32,988,316)

   Provision for income taxes

Net loss and comprehensive loss

$ (16,526,701)

$ (17,042,159)

$ (28,602,783)

$ (32,988,316)

Basic and diluted net loss per share

$            (0.12)

$            (0.13)

$            (0.21)

$            (0.25)

Basic and diluted weighted average number of common shares outstanding 

139,173,746

133,463,300

137,959,958

130,683,671

 

SOURCE Avanir Pharmaceuticals, Inc.



RELATED LINKS

http://www.avanir.com